Michal Zapotocky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michal Zapotocky has a total of 876 co-authors. Here are the top co-authors by number of shared publications:
- Cynthia Hawkins
Division of Pathology, The Hospital for Sick Children, Toronto, Canada
51 shared publications - Uri Tabori
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada
44 shared publications - Sébastien Perreault
Department of Neurosciences, University of Montreal, CHU Sainte-Justine, Montreal, QC H3T 1J4, Canada
43 shared publications - Vijay Ramaswamy
Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada
41 shared publications - An Van Damme
Department of Pediatric Hematology Oncology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium
34 shared publications - David S. Ziegler
Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia
34 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure 1 shows an overview of ITCC-P4 PDX engraftment success rates and multi-omics data availability
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure 1 shows an overview of ITCC-P4 PDX engraftment success rates and multi-omics data availability
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S2 shows methylation- and transcriptome-based analyses of ITCC-P4 PDX models
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S2 shows methylation- and transcriptome-based analyses of ITCC-P4 PDX models
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S3 displays a comparison of driver mutation profiles between ITCC-P4 PDX models and matched patient tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S3 displays a comparison of driver mutation profiles between ITCC-P4 PDX models and matched patient tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S4 shows the genomic characterization of ITCC-P4 PDX models and matched patient tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S4 shows the genomic characterization of ITCC-P4 PDX models and matched patient tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S5 shows genomic fidelity between ITCC-P4 PDX models and matched patient tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S5 shows genomic fidelity between ITCC-P4 PDX models and matched patient tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S7 shows Clonal evolution analyses of sequential PDX models.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S7 shows Clonal evolution analyses of sequential PDX models.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S6 displays the methylation-based tSNE analysis of serial PDX models across pediatric cancer entities.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S6 displays the methylation-based tSNE analysis of serial PDX models across pediatric cancer entities.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Table 1: Table resuming the clinical, xenograft and data details for the PDX models in the ITCC-P4 cohort.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Table 1: Table resuming the clinical, xenograft and data details for the PDX models in the ITCC-P4 cohort.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Table 2:List of ITCC-P4 and reference samples included in DNA methylation analyses; PDX-tumor distance Manhattan scores; Methylation-inferred purity scores.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Table 2:List of ITCC-P4 and reference samples included in DNA methylation analyses; PDX-tumor distance Manhattan scores; Methylation-inferred purity scores.